雷傑納隆藥廠
(REGN)

  • 股價
    913.445
  • 漲跌
    6.13
  • 漲幅
    0.68%
  • 成交量
    5,301
YahooFinanceBusiness
The financial world is abuzz with anticipation as the Federal Reserve is expected to cut interest rates later this year. Historically, such a move has proven to be a significant catalyst for small-cap stocks, particularly in the capital-intensive innovation fields. Since the Federal Reserve began h
    YahooFinanceBusiness
    The financial world is abuzz with anticipation as the Federal Reserve is expected to cut interest rates later this year. Historically, such a move has proven to be a significant catalyst for small-cap stocks, particularly in the capital-intensive innovation fields. Since the Federal Reserve began h
      YahooFinanceBusiness
      Over the past year, many Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) insiders sold a significant stake in the company which may have piqued investors' interest. When analyzing insider transactions, it is usually more valuable to know whether insiders are buying versus knowing if they are selling,
        YahooFinanceBusiness
        Most readers would already know that Regeneron Pharmaceuticals' (NASDAQ:REGN) stock increased by 9.6% over the past three months. Given that the market rewards strong financials in the long-term, we wonder if that is the case in this instance. Particularly, we will be paying attention to Regeneron 
          YahooFinanceBusiness
          In this article, we will be taking a look at 11 oversold biotech stocks to buy right now. To skip our detailed analysis of the biotech sector, you can go directly to see the 5 Oversold Biotech Stocks To Buy Right Now.
          Healthcare has been performing well so far in 2024, and many investors are now w
            YahooFinanceBusiness
            Over the past year, many Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) insiders sold a significant stake in the company which may have piqued investors' interest. Knowing whether insiders are buying is usually more helpful when evaluating insider transactions, as insider selling can have various ex
              YahooFinanceBusiness
              Using the 2 Stage Free Cash Flow to Equity, Regeneron Pharmaceuticals fair value estimate is US$1,665
              Current share price of US$969 suggests Regeneron Pharmaceuticals is potentially 42% undervalued
              Our fair value estimate is 64% higher than Regeneron Pharmaceuticals' analyst price target of US$1,
                YahooFinanceBusiness
                Eli Lilly has been on a roll. The big drugmaker won U.S. regulatory approval for weight loss drug Zepbound in November 2023. Over the last 12 months, Lilly's share price has skyrocketed more than 140%. Lilly has also claimed the mantle of the biggest healthcare company in the world based on market